bioAffinity Technologies closes $3.2M public offering

bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW) announced the closing of a public offering that raised $3.2 million in gross proceeds, before deducting agent fees and other expenses, according to a company press release.

The offering consisted of 4,000,000 shares of common stock at a purchase price of $0.80 per share, with a par value of $0.007 per share. Pre-funded warrants were also available in lieu of shares at a price of $0.793 per warrant, each exercisable for one share of common stock. The warrants are immediately exercisable and expire upon full exercise.

The closing was expected to occur on or about June 18, 2026, subject to customary closing conditions. WallachBeth Capital, LLC served as the sole placement agent for the offering.

The securities were offered pursuant to a registration statement on Form S-1 previously filed with and declared effective by the Securities and Exchange Commission.

bioAffinity Technologies is a San Antonio, Texas-based biotechnology company focused on noninvasive tests for the detection of early-stage lung cancer and other lung diseases.

You May Also Be Interested In

• Centrus Energy extends tax protection rights plan through 2029
• BTQ Technologies launches ATM program to sell up to C$150M in shares
• Senti Biosciences (SNTI) files for 15.97M share offering by selling stockholders